Download fulltext HTML
1.
Karimi S, Arabi A, Shahraki T, Safi S. Central Serous Chorioretinopathy in a Case of Regressed Familial Retinoblastoma. JOVR [Internet]. 2020Oct.25 [cited 2024Apr.19];15(4):559–564. Available from: https://knepublishing.com/index.php/JOVR/article/view/7802

https://doi.org/10.18502/jovr.v15i4.7802

statistics

  • 563 Abstract Views
  • 350 PDF Views
  • 0 HTML Views

authors

  • Saeed Karimi

    Saeed Karimi

    Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Torfe Medical Center, Tehran, Iran
  • Amir Arabi

    Amir Arabi

    Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Torfe Medical Center, Tehran, Iran
  • Toktam Shahraki

    Toktam Shahraki

    Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Torfe Medical Center, Tehran, Iran
  • Sare Safi

    Sare Safi

    Ophthalmic Epidemiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Published Date

  • Oct 25, 2020
This journal is publishing all the articles under Creative Commons Attribution License CC BY 4.0.

Central Serous Chorioretinopathy in a Case of Regressed Familial Retinoblastoma

Journal of Ophthalmic and Vision Research (JOVR) / October–December 2020, Volume 15, Issue 4 / Pages 559–564

Abstract

Purpose: To present a case of central serous chorioretinopathy (CSC) in association with regressed familial retinoblastoma.


Case Report: A 23-year-old man with regressed unilateral familial retinoblastoma in his left eye presented with decreased vision of the left eye since two months ago. The patient had undergone chemotherapy and cryotherapy for the treatment of retinoblastoma 20 years ago. In the left eye, funduscopy disclosed regressed mass of retinoblastoma, inferonasal to the optic disc, and focal subfoveal neurosensory detachment. Optical coherence tomography (OCT) and fluorescein angiography revealed CSC. As there was no sign of recurrence of retinoblastoma and retinal findings did not show late-onset chemotherapy-related retinopathy, the patient was diagnosed with CSC and followed up. After two months, visual acuity of the left eye improved, and repeated macular OCT revealed absorption of the subretinal fluid.


Conclusion: Subretinal fluid accumulation in a patient with regressed retinoblastoma is not always a sign of tumor recurrence or a treatment-related retinopathy.

Keywords:

Central Serous Chorioretinopathy, Recurrence, Retinoblastoma

References
1. Spaide RF, Goldbaum M, Wong DW, Tang KC, Iida T. Serous detachment of the retina. Retina 2003;23:820–846.

2. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004;111:244–249.

3. Islam QU, Hanif MK, Tareen S. Frequency of systemic risk factors in central serous chorioretinopathy. J Coll Physicians Surg Pak 2016;26:692–695.

4. Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Retina 2012;32:709.

5. Wakakura M, Ishikawa S. Central serous chorioretinopathy complicating systemic corticosteroid treatment. Br J Ophthalmol 1984;68:329–331.

6. Jain IS, Singh K. Maculopathy a corticosteroid side-effect. J All India Ophthalmol Soc. 1966;14:250–252.

7. Chumbley LC, Frank RN. Central serous retinopathy and pregnancy. Am J Ophthalmol 1974;77:158–160.

8. Bouzas EA, Scott MH, Mastorakos G, Chrousos GP, Kaiser-Kupfer MI. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol 1993;111:1229–1233.

9. Thoelen AM, Bernasconi PP, Schmid C, Messmer EP. Central serous chorioretinopathy associated with a carcinoma of the adrenal cortex. Retina 2000;20:98–99.

10. Krishna SM, Yu GP, Finger PT. The effect of race on the incidence of retinoblastoma. J Pediatr Ophthalmol Strabismus 2009;46:288–293.

11. Bellerive C, Singh AD. Radiation retinopathy 47 years following brachytherapy for retinoblastoma. Ocul Oncol Pathol 2018;4:157–160.

12. Kim SJ, Hubbard GB, 3rd. Intravitreal bevacizumab (avastin) for radiation retinopathy 53 years after treatment of retinoblastoma. Retin Cases Brief Rep 2007;1:198–201.

13. Shields CL, Piccone MR, Shields JA, Eagle RC, Jr., Singer M. Mushroom-shaped choroidal recurrence of retinoblastoma 25 years after therapy. Arch Ophthalmol 2002;120:844–846.

14. Katz BJ, Ward JH, Digre KB, Creel DJ, Mamalis N. Persistent severe visual and electroretinographic abnormalities after intravenous Cisplatin therapy. J Neuro-Ophthalmol 2003;23:132–135.

15. Kwan AS, Sahu A, Palexes G. Retinal ischemia with neovascularization in cisplatin related retinal toxicity. Am J Ophthalmol 2006;141:196–197.

16. Sioufi K, Say EAT, Ferenczy SC, Leahey AM, Shields CL. Optical coherence tomography angiography findings of deep capillary plexus microischemia after intravenous chemotherapy for retinoblastoma. Retina 2019;39:371– 378.

17. Berry JL, Kogachi K, Murphree AL, Jubran R, Kim JW. A review of recurrent retinoblastoma: Children’s Hospital Los Angeles Classification and Treatment Guidelines. Int Ophthalmol Clin 2019;59:65–75.

18. Shields CL, Honavar SG, Shields JA, Demirci H, Meadows AT, Naduvilath TJ. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 2002;120:460–464.

19. Shields CL, Shelil A, Cater J, Meadows AT, Shields JA. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch Ophthalmol 2003;121:1571– 1576.

20. Munier FL. Classification and management of seeds in retinoblastoma. Ellsworth Lecture Ghent August 24th 2013. Ophthalmic Genet 2014;35:193–207.

21. Dada T. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 2000;130:379.

22. Kim JT, Eichling PS, Wang M. Central serous chorioretinopathy associated with narcolepsy. Retin Cases Brief Rep 2011;5:302–305.

23. Peiretti E, Slakter JS, Wu S, Iranmanesh R, Yannuzzi LA. Late effect of external eye irradiation on choroidal circulation. Eur J Ophthalmol 2006;16:637–640.